Biomarkers to distinguish between RA and OA patients | All the latest summaries on the portal Medznat.ru. :- Medznat
EN | RU
EN | RU

Help Support

By clicking the "Submit" button, you accept the terms of the User Agreement, including those related to the processing of your personal data. More about data processing in the Policy.
Back

Biomarkers to distinguish between RA and OA patients

Biomarkers to distinguish between RA and OA patients Biomarkers to distinguish between RA and OA patients
Biomarkers to distinguish between RA and OA patients Biomarkers to distinguish between RA and OA patients

Presently published data considering the potential role of OPG, OCN and OPN to distinguish between RA and OA are contradictory. 

See All

Key take away

Recently, many studies have reported new biomarkers to identify RA, for example, osteoprotegerin (OPG), osteocalcin (OCN) and osteopontin (OPN). This study revealed that the plasma/serum OPG, OCN and OPN levels were almost similar in RA and OA patients. Hence, it may stipulate that race may correlate with OPG, OCN and OPN levels in rheumatoid arthritis (RA) patients. Also, the expression of OPN in RA patients was significantly higher than in OA patients.

Background

Presently published data considering the potential role of OPG, OCN and OPN to distinguish between RA and OA are contradictory. To derive a more precise evaluation, this meta-analysis was performed.

Method

Published pieces of literature comparing plasma/serum OPG, OCN and OPN levels between RA group and OA controls were searched in PubMed, Embase and the Cochrane Library. Newcastle-Ottawa Scale estimated the study quality. Pooled standard mean difference (SMD) with 95% confidence interval (CI) was calculated using the random-effect model analysis. The Heterogeneity test was performed by the Q statistic and quantified using I2.

Result

Nine studies, including 438 RA patients and 255 OA patients were included in the meta-analysis after examining the title, type, abstracts and full text. The results showed that RA patients had higher plasma/serum OPN (pooled SMD = -2.57, 95% CI = -4.72 to -0.41) levels when compared to OA patients. No significant difference in plasma/serum OPG (pooled SMD = -0.29, 95% CI = -1.07‒0.49) and OCN (pooled SMD = -0.09, 95% CI = -0.48‒0.31) levels were found between RA and OA patients. Subgroup analysis indicated that plasma/serum OPG levels had no significant differences between RA patients and OA patients in Europe and Asia.

Conclusion

Overall, there is no significant difference in circulating OPG and OCN levels between RA patients and OA patients. However, plasma/serum OPN level is significantly higher in RA patients compared with OA patients.

Source:

Immunol Invest

Article:

Circulating Levels of Osteoprotegerin, Osteocalcin and Osteopontin in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

Authors:

Liu LN et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: